Search PubMed⌕ Search

PubMed · 10095415

Recent developments in soft tissue tumors.

Abstract

The field of soft tissue tumor pathology, despite the relative rarity of the lesions concerned, has grown considerably in recent years and has featured very prominently in the academic pathology literature. This stems from the facts that increasing diagnostic sophistication has allowed the continued refinement of classification schemes and the delineation of numerous previously unrecognized 'entities' and that the application of modern cytogenetic and molecular genetic techniques has revealed the remarkable importance of reproducible cytogenetic aberrations in our understanding of the pathobiology of this group of neoplasms. This presentation will aim to summarize data regarding some of the recently characterized entities as well as the major molecular genetic advances. Newly characterized 'entities' which are important because of the ease with which they are confused with lesions of very different biologic potential include chondroid lipoma, pleomorphic hyalinising angiectatic tumor, extrapleural solitary fibrous tumor, giant cell angiofibroma, cellular angiofibroma, retiform hemangioendothelioma, composite hemangioendothelioma and low grade fibromyxoid sarcoma. The 'hemangioendotheliomas' also represent an important area of conceptual evolution as we begin to more critically analyze the concept of borderline malignancy. Concerning molecular genetic advances, the most striking data to emerge are the frequency of tumour-specific reciprocal translocations, the frequency of biologically revealing cytogenetic aberrations in benign lesions and the emerging evidence of striking differences in cell cycle abnormalities in the different sarcoma types.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

C D Fletcher. 1998. Recent developments in soft tissue tumors.. https://pubmed.ncbi.nlm.nih.gov/10095415/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Recurrent and residual juvenile angiofibromas.

INTRODUCTION: In the surgical management of juvenile nasopharyngeal angiofibromas the possibility of recurrences and residual tumours is always there. This study was undertaken to predict the prognostic factors determining recurrence of juvenile nasopharyngeal angiofibroma and to find out the usual sites of these tumours. MATERIAL AND METHODS: The medical records of 95 patients with histologically proven juvenile nasopharyngeal angiofibroma were reviewed retrospectively. The commonest surgical approach used was a combined transpalatal and transmaxillary approach with a lazy S incision. A conservative lateral infratemporal approach was used in three cases. RESULTS: Complete removal of the juvenile nasopharyngeal angiofibroma was achieved in 78 (82 per cent) of the cases in a single operation. A residual tumour was found in 17 (18 per cent) cases and recurrences occurred in 13 (13.7 per cent) cases. CONCLUSIONS: Extensions into the pterygoid fossa and basisphenoid, erosion of the clivus, intracranial extensions medial to the cavernous sinus, invasion of the sphenoid diploe through a widened pterygoid canal, feeders from the internal carotid artery, a young age and a residual tumour were risk factors found associated with recurrence of juvenile nasopharyngeal angiofibroma.

Angiofibroma↗

Comprehensive genomic analysis identifies MDM2 and AURKA as novel amplified genes in juvenile angiofibromas.

BACKGROUND: Frequent beta-catenin mutations have been detected in juvenile angiofibromas, but the tumor pathogenesis remains unknown. METHODS: Metaphase-comparative genomic hybridization (CGH) was used to identify chromosomal aberrations in 29 tumor specimens. Two tumors were investigated using genome DNA microarrays. RESULTS: Three hundred eleven chromosomal gains and losses were detected by metaphase-CGH. Frequent chromosomal gains were detected at 4q, 6, 12, and X, while frequent chromosomal losses affected regions of chromosomes 8, 16, 17, 22, and Y. Genome DNA microarray analysis in 2 tumors of the series confirmed chromosomal aberrations, detected by metaphase-CGH, and indicated genes such as AURKA (20q13.2) not being recognized by metaphase-CGH. CONCLUSION: Metaphase-CGH results confirmed numerous chromosomal aberrations in juvenile angiofibromas. The most frequent aberrations affected sex chromosomes. Further consensus regions of chromosomal aberrations were detected at 4q, 6, 8, 12, 16, 17, and 22. AURKA and MDM2 were identified as interesting novel amplified genes in juvenile angiofibromas.

Angiofibroma↗